BlossomHill Therapeutics, Inc. Operating Cash Flow
BlossomHill Therapeutics, Inc. (BLSM) reported Operating Cash Flow of -$44.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-18
- 2026-06-30: Net Cash Provided by (Used in) Operating Activities 6 month -$44.17M.
- 2025-06-30: Net Cash Provided by (Used in) Operating Activities 6 month -$20.12M.
| Period end | Net Cash Provided by (Used in) Operating Activities 6 month |
|---|---|
| 2026-06-30 | -$44.17M 10-Q · filed 2026-09-18 |
| 2025-06-30 | -$20.12M 10-Q · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |